https://www.selleckchem.com/pr....oducts/lenalidomide-
More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) in BC patients with de novo stage IV bone only metastasis (BOM). The prospective, multicenter registry study BOMET MF14-01 was initiated in May 2014. Patients with de novo stage IV BOM BC were divided into two groups those receiving systemic treatment (ST group) and those receiving LRT (LRT group). Patients who receiv
Like
Comment
Share
